Matt Abernethy, Chief Financial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 2,704 shares at $132.85 ($359K) on 2024-02-13, disclosed to the SEC on 2024-02-15.
Scheduled sale ($359k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $132.85 | 1,352 | $180K | 50.0% |
| 2 | $132.85 | 1,352 | $180K | 50.0% |
| Total | $132.85 avg | 2,704 | $359K | 100% |
| Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $392K | — | Filing → |
| NBIX | SELL | 2024-08-15 | $2.1M | — | Filing → |